- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen's ProstaScint wins FDA nod
The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year. ProstaScint is licensed
The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year.
ProstaScint is licensed for two indications: to image newlydiagnosed patients whose biopsy-proven prostate cancer is at highrisk of metastasizing to pelvic lymph nodes, and for post-prostatectomypatients in whom there is a suspicion of cancer recurrence.
Cytogen has licensed ProstaScint rights for the urologicalmarket to C.R. Bard's urologic division, while Cytogen will retainrights to the medical imaging market (SCAN 8/28/96).
Cytogen is hoping that ProstaScint will prove to be more successfulthan its OncoScint CR/OV product for imaging colorectal and ovariancancer. The company plans to support ProstaScint through its Partnersin Excellence program, which is designed to help ensure that nuclearmedicine physicians are reading monoclonal antibody scans correctly(SCAN 9/25/96).
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.
AI Mammography Platform Shows Promising Results for Detecting Subclinical Breast Cancer
October 3rd 2024Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.
